Working… Menu

Open-Label Study to Evaluate Mirvetuximab Soravtansine in Cancers With High Folate Receptor-Alpha Expression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05041257
Recruitment Status : Recruiting
First Posted : September 13, 2021
Last Update Posted : September 13, 2021
IQVIA Biotech
Information provided by (Responsible Party):
ImmunoGen, Inc.

Brief Summary:
This is a Phase 2, multicenter, open label study designed to evaluate the safety and efficacy of MIRV in participants with platinum-sensitive ovarian cancer and high folate receptor alpha (FRα) expression

Condition or disease Intervention/treatment Phase
Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer Drug: Mirvetuximab soravtansine Phase 2

Detailed Description:
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of subjects with recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Patients will have had at least 2 prior lines of therapy. These will include at least 2 lines of platinum-containing therapy or 1 line with a documented platinum allergy. FRα positivity will be defined by the Ventana FOLR1 (FOLR1- 2.1) CDx assay (Ventana FOLR1 Assay)

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 75 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Estimated Study Start Date : August 31, 2021
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : May 31, 2024

Arm Intervention/treatment
Experimental: Mirvetuximab Soravtansine
Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
Drug: Mirvetuximab soravtansine
Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
Other Names:
  • MIRV
  • IMGN853

Primary Outcome Measures :
  1. Assess Objective Response Rate [ Time Frame: up to 2 years ]
    Objective response rate (ORR), which includes confirmed best response of complete response (CR) or partial response (PR) as assessed by the Investigator

Secondary Outcome Measures :
  1. Assess Duration of response (DOR) [ Time Frame: up to 2 years ]
    Duration of response (DOR), defined as the time from initial Investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the Investigator

  2. Assess treatment emergent adverse events (TEAEs) [ Time Frame: up to 2 years ]
    Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term

  3. Assess Cancer Antigen-125 [ Time Frame: up to 2 years ]
    Cancer Antigen-125 response determined using the Gynecologic Cancer Intergroup (GCIG) criteria

  4. Assess Progression-free survival (PFS) [ Time Frame: up to 2 years ]
    Progression-free survival (PFS), defined as the time from first dose of MIRV until Investigator-assessed radiological PD or death, whichever occurs first

  5. Assess Overall survival (OS) [ Time Frame: up to 2 years ]
    Overall survival (OS), defined as the time from first dose of MIRV until death

  6. Sensitivity analysis [ Time Frame: up to 2 years ]
    ORR, DOR, and PFS by blinded independent central review (BICR) will be summarized as sensitivity analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Patients ≥ 18 years of age
  2. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  3. Patients must have a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer
  4. Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression
  5. Patients must have progressed radiographically on or after their most recent line of anticancer therapy
  6. Patients must have at least 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator)
  7. Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity
  8. Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay
  9. Prior anticancer therapy

    1. Patients must have received at least 2 prior systemic lines of anticancer therapy including at least 2 prior lines of therapy containing a platinum, and be considered by Investigator as appropriate for single-agent non-platinum therapy (documentation required regarding reason[s] that patient is not appropriate for further platinum therapy - eg, high risk of hypersensitivity reaction given prior cumulative exposure to platinum; risk of further cumulative toxicity with additional platinum, including but not limited to myelosuppression, neuropathy, renal insufficiency) Note: Patients who have had a documented platinum allergy may have had only 1 prior line of platinum
    2. Patients must have had testing for breast cancer susceptibility gene (BRCA) mutation (tumor or germline) and, if positive, must have received a prior poly (ADP-ribose) polymerase ( (PARP) inhibitor as either treatment or maintenance therapy
    3. Neoadjuvant ± adjuvant therapies are considered 1 line of therapy
    4. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)
    5. Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
    6. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
  10. Patients must have completed prior therapy within the specified times below:

    1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to first dose of MIRV
    2. Focal radiation completed at least 2 weeks prior to first dose of MIRV
  11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia)
  12. Patients must have completed any major surgery at least 4 weeks prior to first dose of MIRV and have recovered or stabilized from the side effects of prior surgery prior to first dose of MIRV
  13. Patients must have adequate hematologic, liver and kidney functions defined as:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500/μL) without granulocyte colony-stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 20 days
    2. Platelet count ≥ 100 x 10^9/L (100,000/μL) without platelet transfusion in the prior 10 days
    3. Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days
    4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
    6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN)
    7. Serum albumin ≥ 2 g/dL
  14. Patients must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements
  15. Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) while on MIRV and for at least 3 months after the last dose
  16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV

Key Exclusion Criteria-

  1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumor
  2. Patients with prior wide-field radiotherapy (RT) affecting at least 20% of the bone marrow
  3. Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE)
  4. Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision
  5. Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:

    1. Active hepatitis B or C infection (whether or not on active antiviral therapy)
    2. HIV infection
    3. Active cytomegalovirus infection
    4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV

    Note: Testing at screening is not required for the above infections unless clinically indicated.

  6. Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
  7. Patients with clinically significant cardiac disease including, but not limited to, any of the following:

    1. Myocardial infarction ≤ 6 months prior to first dose
    2. Unstable angina pectoris
    3. Uncontrolled congestive heart failure (New York Heart Association > class II)
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
    5. Uncontrolled cardiac arrhythmias
  8. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment
  9. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
  10. Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis
  11. Patients requiring use of folate-containing supplements (eg, folate deficiency)
  12. Patients with prior hypersensitivity to monoclonal antibodies (mAb)
  13. Women who are pregnant or breastfeeding
  14. Patients who received prior treatment with MIRV or other FRα-targeting agents
  15. Patients with untreated or symptomatic central nervous system (CNS) metastases
  16. Patients with a history of other malignancy within 3 years prior to enrollment

    Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.

  17. Prior known hypersensitivity reactions to study drugs and/or any of their excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05041257

Layout table for location contacts
Contact: Michael Method, MD, MPH, MBA 781-895-0600
Contact: Noam Ponde, MD

Layout table for location information
United States, New Jersey
Holy Name Medical Center Recruiting
Teaneck, New Jersey, United States, 07666
Sponsors and Collaborators
ImmunoGen, Inc.
IQVIA Biotech
Layout table for additonal information
Responsible Party: ImmunoGen, Inc. Identifier: NCT05041257    
Other Study ID Numbers: IMGN853419
First Posted: September 13, 2021    Key Record Dates
Last Update Posted: September 13, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ImmunoGen, Inc.:
Ovarian cancer
Folate-receptor alpha expression
Antibody-drug conjugate
Ovarian Neoplasma
Recurrent Platinum-Sensitive,
High-Grade Ovarian
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action